Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | BDKRB1 | P46663 | 6/20 | 0.60 |
| ▸ | ACLY | P53396 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SLC25A1 | P53007 | 1/20 | 0.58 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.56 |
| ▸ | CCR2 | P41597 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CCR4 | P51679 | 2/20 | 0.56 |
| ▸ | CCR5 | P51681 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2530071 | 0.89 | LMNA (0.74) | KMT2ALMNAACLYHTTCCR2 | |
| SCHEMBL34475240 | 0.88 | MEN1 (0.78) | KMT2AMEN1LMNAACLYSLC25A1 | |
| SCHEMBL13146484 | 0.88 | LMNA (0.60) | KMT2AMEN1LMNABDKRB1ACLY | |
| SCHEMBL13146485 | 0.87 | ACLY (0.60) | KMT2AMEN1LMNABDKRB1ACLY | |
| SCHEMBL10223155 | 0.86 | CCR2 (0.63) | KMT2AMEN1LMNABDKRB1ACLY | |
| SCHEMBL2534648 | 0.85 | BDKRB1 (0.73) | KMT2AMEN1LMNABDKRB1HTT | |
| SCHEMBL31305 | 0.83 | BDKRB1 (0.72) | KMT2AMEN1LMNABDKRB1HTT | |
| SCHEMBL10223159 | 0.82 | CCR2 (0.59) | KMT2AMEN1LMNAACLYPTGES2 | |
| SCHEMBL643467 | 0.82 | LMNA (0.66) | KMT2AMEN1LMNAACLYHTT | |
| SCHEMBL13146596 | 0.81 | MEN1 (0.54) | KMT2AMEN1LMNAACLYHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| WO-2008008374-A2 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008374-A2 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | KMT2A 2576/4885MEN1 4867/4885LMNA 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.